One lawmaker yelled, “This is a bad bill.” Others booed as Klick argued that her bill would legalize medical cannabis in the most narrow way possible. It only allowed the sale of specific medical cannabis products if they contained low levels of tetrahydrocannabinol — the psychoactive element in marijuana known as THC — to Texans with intractable epilepsy who had already tried two Food and Drug Administration-approved drugs and found them to be ineffective. Patients also needed to be permanent Texas residents and get approval from two doctors listed on the Compassionate Use Registry of Texas.
Getting her measure across the finish line in the House amounted to nothing short of a floor fight. Yet the bill, dubbed the Compassionate Use Act, ultimately passed both chambers that year, sending it to Gov. Greg Abbott, who later signed it into law. Three dispensaries have since opened in Texas.
Now, nearly four years later, a broad coalition of lawmakers plus some powerful lobbyists support expanding access to medical cannabis in Texas. But bills to do so face a major obstacle: Lt. Gov. Dan Patrick, the Senate’s presiding officer, who can single-handedly block any legislation from coming up for a vote in the upper chamber.
In a statement to The Texas Tribune, Patrick spokesperson Alejandro Garcia said the lieutenant governor is “strongly opposed to weakening any laws against marijuana [and] remains wary of the various medicinal use proposals that could become a vehicle for expanding access to this drug.”
House Speaker Dennis Bonnen hasn’t publicly expressed a position on expanding the Compassionate Use Act, but he voted against the bill in 2015. According to a person familiar with his thinking, he does not plan to get in the way of the chamber if there is support for amending the program.
Klick, who did not respond to request for comment, is one of a handful of lawmakers this session who has put forth a bill to expand the list of patients eligible for the drug. If passed, her measure would give Texans with multiple sclerosis, epilepsy and spasticity access to medical cannabis.
In addition to Klick’s bill, state Sen. Donna Campbell, R-New Braunfels, filed a bill that would increase the cap on THC levels in medical cannabis legally grown in Texas from 0.5 percent to nearly 1 percent, and allow physicians on the state’s Compassionate Use Registry to decide which patients need it rather than restricting it to those with certain conditions. Two other measures filed by Democrats would drastically expand the list of debilitating medical conditions that qualify for the drug.
It’s not unusual for the more conservative upper chamber to stall marijuana-related bills. A Compassionate Use Act expansion bill in 2017 from state Sen. José Menéndez, D-San Antonio, never received a hearing.
“I don’t understand why politicians are trying to get between the doctor and the patient on something that doesn’t do anything but help the patient,” said Menéndez, who also filed a bill this session that would expand the list of debilitating medical conditions that qualify for medical cannabis to include illnesses like terminal cancer, autism, Crohn’s disease and post-traumatic stress disorder. “Why are we sticking our heads in the sand?
“I can’t give up on all the people who have put their confidence on my working hard on this issue, and I’m not going to.”
But Patrick isn’t the only one skeptical of an expansion measure. Law enforcement groups have also said they fear expanding medical cannabis in the state would lead to the full-blown legalization of marijuana.
“Let’s not sugarcoat it,” said Mitch Slaymaker, deputy executive director for the Texas Municipal Police Association, whose expertise is not in the realm of what constitutes a need for medical marijuana. “Our concern is that expanding medical cannabis is slowly inoculating the public a little more to where it may eventually be fully legalized.”
The association’s main concern, he said, is that if fully decriminalized law enforcement won’t be able to test drivers to determine how affected they are.
Even Campbell, whose Senate Bill 2416 would also establish a review board to approve and oversee research of higher THC cannabis oil for medical purposes, said she agreed with the sentiments put forth by Patrick. “That’s why she introduced a medical cannabis oil bill based on what the Legislature previously passed, with a heavy emphasis on medically driven research,” spokeswoman Alice Claiborne said.
“The senator has great respect for Lt. Gov. Patrick and looks forward to working closely with his office on this subject matter,” Claiborne added.
But it’s unclear if any such measure will even draw a hearing this year, let alone get debated before the full Senate. Matthew Russell, a spokesman for state Sen. Lois Kolkhorst, the Brenham Republican who chairs the Senate Health & Human Services Committee, said the panel was “still reviewing the proposed legislation and gathering information.”
“No decision has been made on either piece of legislation,” Russell said of Menéndez’s and Campbell’s bills.
The House, meanwhile, is handling marijuana-related bills with a different speed and tone. Two years ago, Democratic state Rep. Eddie Lucio III of Brownsville filed a measure that would’ve expanded the program to patients with medical conditions such as terminal cancer and PTSD. More than half of the Texas House — nearly 80 members — signed on as authors, co-authors or joint authors, yet it didn’t make it to the floor in time for a vote. Lucio filed a similar bill this session that would expand the list of debilitating medical conditions that qualify for the oil to include autism and Crohn’s disease, among others.
In 2017, “we moved a comprehensive medicinal marijuana bill further than anyone ever has in the Legislature,” Lucio said. “There was such broad support, and I think it’s grown even more so since then. It’s discussed even more openly now.”
One sign in support of Lucio’s reading of the chamber: Last week, Democratic state Rep. Senfronia Thompson of Houston, who chairs the House Public Health Committee, created a subcommittee on medical marijuana to hear just proposals related to the issue.
“There are so many things we want to do to make [medical marijuana] legally available to help people if it can help them,” Thompson said. “I’m assuming the public wants to have a say on this issue, and I’m trying to do my best to give them a say.”
And although the Senate may refuse to budge on medical expansion bills, Thompson said they would still receive a fair shake in the lower chamber.
“If the Senate wants to take another position, then that’s on them,” Thompson said. “I’m just going to do what I can do from where I stand.”
Abbott, for his part, said in 2015 that Texas lawmakers wouldn’t approve legislation that would legalize marijuana. A spokesperson for Abbott did not respond to request for comment on whether he’d back an expansion of the current medical cannabis system.
Still, the effort to expand the Compassionate Use Act has drawn some politically powerful supporters since the last legislative session. In its most recent platform, the Republican Party of Texas approved a plank asking the Legislature to “improve the 2015 Compassionate Use Act to allow doctors to determine the appropriate use of cannabis to certified patients.”
And earlier this month, a new group lobbying for medical marijuana emerged comprising players with some serious clout in the Capitol — including Allen Blakemore, a top political consultant for Patrick.
Texans for Expanded Access to Medical Marijuana, dubbed TEAMM, said it will work to educate the public and lawmakers about the benefits of expanding medical cannabis to those with illnesses like cancer and traumatic brain injury. The group is backed by Green Peak Innovations, a Michigan-based medical cannabis firm.
According to a poll commissioned by TEAMM, 81 percent of Texas voters support the expansion of medical marijuana and 86 percent believe that doctors and researchers — as opposed to the state — should decide when patients have access to medical marijuana.
“This is one of the last true bipartisan issues out there,” said Brian Sweany, a member of TEAMM’s leadership. “I don’t think it surprises anyone how high support is for this among Democrats, but people who identify as conservative Republicans also overwhelmingly support this.”
More than 30 states allow the use of marijuana for medicinal purposes, according to the National Conference of State Legislatures. Texas is one of nearly a dozen states that only allows for “low THC, high CBD” products for medical situations in limited circumstances.
“We’re going to do our job in the House, and the bill that gets out of the House — whether it’s mine or Klick’s or some compromise of the two — is going to help a lot of people,” Lucio said. “If it gets to the Senate, then it’s up to the lieutenant governor to make that decision, and he has to answer to the Texans who overwhelmingly support this.”
This article originally appeared in The Texas Tribune.
The Texas Tribune is a nonprofit, nonpartisan media organization that informs Texans — and engages with them — about public policy, politics, government and statewide issues.
(Disclosure: Allen Blakemore has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune’s journalism. Find a complete list of them here.)
Photo element courtesy of Gage Skidmore.
Federal Court Dismisses Suit Against DEA Over Marijuana Growing Applications
A federal court dismissed a lawsuit against the Drug Enforcement Administration (DEA) on Friday after determining that the agency had fulfilled a requirement to process applications for research-grade marijuana manufacturers.
DEA was sued in June after declining to act on the more than two dozen applications that it received for approval to cultivate cannabis for research purposes. It’s been more than three years since the agency first announced it was opening the process to consider additional producers.
The suit, brought by the Scottsdale Research Institute (SRI), argued that the marijuana grown at the University of Mississippi—currently the only facility that’s federally authorized to cultivate the plant—is of poor quality, does not reflect the diversity of products available on the commercial market and is therefore inadequate for clinical studies.
Indeed, that’s a point that several policymakers have made, and it’s bolstered by research demonstrating that the federal government’s cannabis is genetically closer to hemp than marijuana that consumers can obtain in state-legal markets.
In July, the U.S. Court of Appeals for the District of Columbia Circuit ordered DEA to respond to the legal challenge within 30 days—and as that deadline approached in August, the agency published a notice in the Federal Register stating that it was taking steps to approve the pending applications.
Due to the volume of the applications, DEA said it would have to develop alternative rules to process them. And on Friday the court said that DEA had fulfilled its obligations and that the suit “is now moot.” While no applications have been approved to date, there’s a public comment period that will last until October 28 and then the agency will have an additional 90 days to take action on the inquiries.
“The Court dismissed our case because, according to the Court, DEA gave us the relief we had requested,” attorney Matt Zorn, who was involved in the suit, told Marijuana Moment. “Last week, on October 11, DEA published a correction to the notice it had previously published on August 26, two days before it had to respond to the Court’s order. The Court said this second notice meant there was nothing more the Court could give us.”
“The Court also declined to maintain jurisdiction over the case, because it did not find a history of chronic delay or bad faith in the record,” Zorn said. “But it also indicated that we could return to court if DEA significantly delays going forward.”
Sue Sisley, a researcher with SRI, said that despite the case being dismissed, it “moved the ball forward for everyone.”
“We would have liked to take the case one step further to ensure that all 33 applications are processed promptly—protecting the health and welfare of our nation’s medically ill patients ought to be a national priority for this administration,” she said. “By delaying these 33 applications, the administration has prevented our US scientists from investigating the clinical efficacy of real-world cannabis to treat combat veterans with PTSD. Fortunately, the Court’s order today allows us to return to court for additional relief if Trump’s DOJ/DEA continues to violate the law and put public health at risk through delay or otherwise.”
In a separate case in May, another federal court ordered DEA to “promptly” consider applications to reschedule cannabis under the Controlled Substances Act.
Read the appeals court’s ruling on the DEA marijuana application case below:
Former VA Secretary Who Oversaw Marijuana Research Blockade Now Backs Cannabis Studies For Veterans
Former U.S. Department of Veterans Affairs (VA) Secretary David Shulkin is officially on board with having the department research medical marijuana—a development that comes a year after he was in a position to actually make that happen.
In an interview with Task & Purpose that was published on Thursday, Shulkin said that “the time is now” for VA to facilitate studies into the therapeutic potential of cannabis for veterans.
“I believe that the VA should be involved in research on anything that could potentially help veterans and improve their health and well-being,” he said.
That appears to represent a notable departure from the position he held while he headed the department.
For example, VA under his leadership refused to provide assistance to an Arizona-based research facility that was soliciting veterans to participate in a federally approved clinical trial looking at the potential benefits of cannabis in the treatment of post-traumatic stress disorder (PTSD).
“Federal law restricts VA’s ability to conduct research involving medical marijuana, or to refer veterans to such research projects,” a VA official told Air Force Times in 2017. “The researcher is free to work with veterans service organizations and state veterans officials who may not face such restrictions to identify candidates for her study.”
But according to the Brookings Institute, that’s not an accurate assessment because “doctors and researchers at the VA or in VA hospitals could conduct research into the medical efficacy of marijuana while remaining completely compliant with federal laws, regulations, and the United States’ obligations under international agreements.”
While the former secretary still said during this latest interview that congressional action is necessary to prompt VA research efforts, he seems to have become decidedly more vocal about the importance of such studies as compared to his time in office.
“In particular, with the VA’s focus on suicide as the top priority, people just don’t take their lives because of no reason,” he said. “They take their lives, often because of issues related to chronic pain, depression, substance abuse, and there is growing evidence that medical marijuana—I’m not talking about recreational marijuana—but properly prescribed, may have some real benefits in anxiety improvement, in pain management, and potentially, in the issue of substance abuse.”
“And therefore, I believe it’s extremely appropriate for VA to be researching and developing therapies that can help veterans, particularly in areas where we don’t have enough good therapies or answers,” he said.
Task & Purpose followed up to ask about potential obstacles such to having VA conduct research into the issue, and Shulkin said that because marijuana is a federally controlled substance, “the challenge of doing research with the regulations, and the hoops that you have to go through, are making it too difficult to do for many of the researchers.”
“I do think that the way forward is a legislative solution, much of what VA responds to are changes in the law, where medical research for veterans in this area could be streamlined and clarity around what regulations and rules need to be followed to be able to do this research, as well as guidance about the type of research that can and should be done, which reports back to Congress.”
He added that he doesn’t anticipate that President Trump would resist legislation empowering VA to study marijuana for veterans.
Brad Burge, director of strategic communication at the Multidisciplinary Association for Psychedelic Studies (MAPS), the group behind the study into cannabis for PTSD, told Marijuana Moment that they are “pleased that Shulkin has now expressed his support for medical marijuana research, even though that support would have been much more valuable when he was still in office.”
“Nevertheless we are looking forward to the VA’s support of marijuana research and see Shulkin’s change of stance as a promising sign for veterans suffering from PTSD,” Burge said.
It wasn’t just that Shulkin’s VA put up roadblocks to cannabis research, he also resisted providing veterans with access to marijuana by declining to change internal VA policy that could empower its doctors to issue recommendations in states where it’s legal.
The reasoning, he said in 2017, is that it’s “not within our legal scope to study that in formal research programs or to prescribe medical marijuana, even in states where it’s legal” because of federal law. But advocates argued that the only thing standing in the way of VA cannabis research is VA policy itself, which Shulkin could have amended.
Getting a VA cannabis reform bill passed as the former official is now recommending has already proved difficult this year, with current VA officials voicing opposition during a congressional committee hearing in June to modest proposals such as allowing their doctors to recommend cannabis or even surveying veterans about their marijuana use.
Rep. Earl Blumenauer (D-OR) said that same month that he pulled an appropriations amendment to allow for VA marijuana recommendations from floor consideration partly because of opposition from the department.
Mexican Committees Unveil Marijuana Legalization Bill Ahead Of Supreme Court Deadline
Several Mexican Senate committees unveiled draft legislation late on Thursday to legalize marijuana.
Leaders of the Health, Justice, Public Security and Legislative Studies Committees announced last week that they would remain in permanent session to finalize the legalization bill ahead of a coming Supreme Court deadline.
The court determined last year that the country’s ban on personal cannabis consumption and cultivation is unconstitutional, though lawmakers now want to go even further by legalizing commercial production and sales.
The committees are expected to formally vote on the legislation in the coming days, after which point it will head to the full Senate and then the Chamber of Deputies. Leaders said a vote in the legislature could occur before the end of the month, though it’s possible they could ask the Supreme Court for a deadline extension.
Ayer, antes de medianoche, fue entregado a los senadores de las comisiones de Justicia, Salud, Estudios Legislativos, Segunda y Seguridad Pública el predictamen📃🌿 de la ‘Ley para la regulación de la cannabis’. Está conformado por 74 artículos y once transitorios. pic.twitter.com/8IKOF7pA1i
— Cáñamo México (@canamo_mexico) October 18, 2019
Here are some of the key provisions, according to a translation:
—Adults 18 and older can possess cannabis for personal use, cultivate up to four plants and purchase marijuana from licensed retailers.
—An independent body called the “Cannabis Institute” would be charged with issuing licenses, setting potency limits and monitoring the implementation of the law, among other responsibilities.
—Low-income individuals, small farmers and indigenous people would have licensing priority.
—Strict restrictions would be imposed on cannabis packaging. That includes requiring nondescript, standardized containers that do not feature depictions of real or fictional people or testimonials.
—Marijuana can only be consumed in private spaces.
—Only medical cannabis patients would be allowed to purchase infused edibles and beverages.
—Unregistered seeds or plants would be subject to forfeiture.
—No pesticides could be used on cannabis plants.
The bill seeks to “improve the living conditions of people living in the United Mexican States, combat the consequences of the problematic use of cannabis and reduce the crime incidence linked to drug trafficking [while] promoting peace, the security and well-being of individuals and communities,” according to the text.
Sen. Julio Menchaca Salazar, head of the Justice Committee, said in a tweet that “we are legislating to regulate the illicit market of the #marihuana and decrease the crime incidence linked to the #narcotráfico, promoting peace and security for all Mexicans.”
— Julio Menchaca S. (@Julio_Menchaca) October 18, 2019
Lawmakers have said that the legislation is largely based on a proposal that Interior Secretary Olga Sánchez Cordero filed last year while still serving as a senator, but the committees are also merging in provisions from among more than a dozen other marijuana reform bills that since have been introduced.
“They all have something good that we can be translating into law,” Menchaca Salazar, who is a member of the ruling MORENA party, said.
Debate on the measure will also be informed by findings from a series of events the Senate organized to gather public input on marijuana legalization. That includes a panel led by a former White House drug czar, who stressed the need for “robust regulations” of a legal cannabis market.
The leader of the MORENA party in the Senate, Sen. Ricardo Monreal, said earlier this month that the chamber was set to vote on a legalization bill ahead of the October 24 deadline.
“It will undoubtedly be a great discussion with the elements we have and also with all the willingness to incorporate the opinions of legislators, but it would come out this month, there are the conditions for that to be,” Menchaca Salazar said.
Read the full text of the Mexican committees’ marijuana legalization proposal below:
This story is developing and will be updated.